Please ensure Javascript is enabled for purposes of website accessibility

Why AbbVie's Stock Jumped in September

By George Budwell - Oct 8, 2019 at 9:47AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

AbbVie's shares reversed course last month. Here's why.

What happened

Shares of biotech giant AbbVie (ABBV -0.11%) gained a healthy 15% in September, according to data from S&P Global Market Intelligence.

The spark? AbbVie's shares perked up after the company's presentation at the Morgan Stanley Healthcare Conference on Sept. 10. While the company didn't reveal anything new during this presentation, CEO Richard Gonzalez's comments about the upcoming Allergan (AGN) acquisition, as well as how the company plans to create value as Humira goes off patent, appear to have gone a long way toward reassuring investors.   

An open road with the word recovery written across it.

Image source: Getty Images.

So what

Prior to last month's rally, AbbVie's shares were down by an unsightly 28% for the year, thanks to the growing concerns about Humira's future. In short, AbbVie's flagship medication has been experiencing a sharper-than-expected drop in international sales following the introduction of biosimilars in Europe. A similar pattern could very well emerge in the U.S. once biosimilars hit the market.  

As Gonzalez noted during this latest investor presentation, though, AbbVie should be able to continue to post industry-leading levels of revenue and earnings growth well into the next decade, even after Humira loses patent protection in the United States. Keeping with this theme, this megamerger with Allergan will immediately lower Humira's overall importance in terms of revenue growth and the biotech now sports a healthy stable of new growth products -- several of which should turn out to be megablockbusters in their own right.

Now what

Can AbbVie's shares continue to rebound? The short answer is yes. AbbVie has been one of the cheapest large-cap biotech stocks for the better part of the last 12 months. So, as the fear over Humira's demise begins to fade and the positive impacts of this Allergen tie-up come into view, AbbVie's shares should begin to garner a more typical valuation for a top biotech.  

 

George Budwell has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AbbVie Inc. Stock Quote
AbbVie Inc.
ABBV
$141.29 (-0.11%) $0.15
Allergan plc Stock Quote
Allergan plc
AGN

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
394%
 
S&P 500 Returns
127%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/18/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.